Abbonarsi

ACELLULAR PERTUSSIS VACCINES - 06/09/11

Doi : 10.1016/S0031-3955(05)70209-1 
Michael D. Decker, MD, MPH a, Kathryn M. Edwards, MD b
a Departments of Preventive Medicine and Medicine (Infectious Diseases) (MDD) 
b Pediatrics (KME), Vanderbilt University School of Medicine, Nashville, Tennessee 

Riassunto

Pertussis (whooping cough) is a bacterial respiratory infection caused by the gram-negative bacillus Bordetella pertussis. Its hallmark is a cough illness that lasts many weeks. A related organism, Bordetella parapertussis, can produce a less severe pertussis-like syndrome. Pertussis may occur at any age (infection of adolescents and adults is increasingly recognized) but is most severe in infants and young children. Infants are susceptible to pertussis within the first few weeks or months of life, when the risk for mortality from whooping cough is highest.

Pertussis is acquired through direct transmission from close respiratory contact and is highly contagious; as many as 90% of susceptible household contacts will acquire the disease. Before the routine use of whole-cell pertussis vaccine, virtually every child experienced pertussis infection; as many as 270,000 cases of pertussis were reported each year in the United States, with 10,000 deaths.15 With vaccination, the prevalence of pertussis declined to a nadir of 1010 reported cases in 197612 but has progressively increased since. The 7796 cases reported for 1996 was the highest total in more than 30 years. Currently, in countries such as the United States, in which pertussis vaccination is common, the age distribution of pertussis has changed markedly. The increase in pertussis has been greatest among older children and adults, probably reflecting waning vaccine-induced immunity. Because pertussis often is undiagnosed in adolescents and adults, the actual number of cases likely greatly exceeds the number reported. Worldwide, an estimated 40 million pertussis cases occurred in 1994, resulting in 5 million episodes of pneumonia, 360,000 deaths, and 50,000 neurologic complications (including permanent brain damage).25

The incubation period averages 9 or 10 days. Onset is gradual; an intermittent cough progresses to paroxysms and the characteristic whoop begins. The whoop is caused by forced inspiration through a narrowed glottis immediately following a paroxysm of a dozen or more rapid, short coughs without intervening inspiration. Cyanosis and vomiting may ensue, and these children often are left exhausted; unfortunately, several paroxysms may occur within a few minutes. Between paroxysms, these children may appear normal. Recovery is gradual. Minor complications include subconjunctival hemorrhages, epistaxis, edema of the face, and ulcer of the frenulum. Major complications include pneumonia, encephalopathy, and wasting.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Michael D. Decker, MD, MPH, Vanderbilt University School of Medicine, A-1116 Medical Center North, Nashville, TN 37232–2637, e-mail: michael.decker@mcmail.vanderbilt.edu


© 2000  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 47 - N° 2

P. 309-335 - aprile 2000 Ritorno al numero
Articolo precedente Articolo precedente
  • POLIOVIRUS VACCINES : Progress Toward Global Poliomyelitis Eradication and Changing Routine Immunization Recommendations in the United States
  • Roland W. Sutter, D. Rebecca Prevots, Stephen L. Cochi
| Articolo seguente Articolo seguente
  • UPDATE ON HAEMOPHILUS INFLUENZAE SEROTYPE b AND MENINGOCOCCAL VACCINES
  • Nancy E. Rosenstein, Bradley A. Perkins

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.